HALAVEN is an FDA-approved chemotherapy that has been prescribed to over 230,000 patients worldwide, in over 70 countries,* with over 65,000
prescribed HALAVEN in the US alone,† offering women with advancing mBC an opportunity to live longer after progressing on 2 other therapies.‡
*Indications may vary in other countries.
†Patient treatment based on estimate of average patient usage provided by IntrinsiQ intelliVIEW™. Total number of vials from November 2010 to March 2020.
‡Therapies should have included an anthracycline and a taxane for early or advanced breast cancer.
HALAVEN is a prescription medicine used to treat adults with breast cancer that has spread to other parts of the body, and who have already received other types of anticancer medicines after the cancer has spread.
HALAVEN can cause serious side effects, including
Before you receive HALAVEN, tell your health care provider about all of your medical conditions, including if you
Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of HALAVEN?
HALAVEN can cause changes in your heartbeat (called QT prolongation). This can cause irregular heartbeats. Your health care provider may do heart monitoring (electrocardiogram or ECG) or blood tests during your treatment with HALAVEN to check for heart problems.
The most common side effects of HALAVEN in adults with breast cancer include low white blood cell count (neutropenia), low red blood cell count (anemia), weakness or tiredness, hair loss (alopecia), nausea, and constipation.
Your health care provider will do blood tests before and during treatment while you are taking HALAVEN.
For more information about HALAVEN, please see full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.